Pmv Pharmaceuticals Inc (PMVP) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pmv Pharmaceuticals Inc   (NASDAQ: PMVP)

Pmv Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Pmv Pharmaceuticals Inc in the second quarter 2026?
Pmv Pharmaceuticals Inc recorded a cumulative net loss of $-75 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -78.11%.

Within the Major Pharmaceutical Preparations industry 228 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2473 to 3308.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -49.15 % -45.06 % -40.53 % -38.86 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -75 -78 -78 -83 -81
Return On Equity (TTM) -78.11 % -68.98 % -59.07 % -55.34 % -47.95 %
PMVP's Total Ranking # 3308 # 2473 # 2362 # 2915 # 2579
Equity (TTM) in Millions 72 88 105 121 141
Seq. Equity Change -18.72 % -15.99 % -13.46 % -13.94 % -12.18 %
Seq. Net Income Change - - - - -

Back to PMVP Management Effectiveness >> PMVP's 5 Years Annual ROE >> Compare PMVP ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 229
Sector # 503
Overall # 3308

Return On Equity Statistics
High Average Low
-6.92 %
-33.23 %
-78.11 %
(Jun 30 2021)   (Jun 30 2026)



  News about Pmv Pharmaceuticals Inc Return on Equity ROE

PMV Pharmaceuticals Reinforces Leadership Team: Spearheading Transformative Cancer Therapies

PMV Pharmaceuticals: Bolstering Leadership for Late-Stage Development Success
PMV Pharmaceuticals, a pioneering precision oncology company specializing in the development of small molecule therapies targeting p53, has recently made strategic appointments to its leadership team. These key additions come as the company advances into late-stage development, solidifying its position as a frontrunner in the field of cancer research.
As the significance of precision medicine continues to gain momentum in the pharmaceutical industry, PMV Pharmaceuticals stands at the forefront, leading the charge in the discovery and development of tumor-agnostic therapies. By targeting the p53 protein, which is frequently mutated in cancer patients, PMV Pharmaceuticals aims to deliver breakthrough treatments that can benefit a wide range of cancer types and patients.



PMVP Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 105 176 226 246 309
Y / Y Equity Change -40.53 % -21.98 % -8.27 % -20.27 % -14.08 %
Net Income in Millions -78 -59 -69 -73 -58
Y / Y Net Income Change - - - - -
Return On Equity -74.24 % -33.34 % -30.56 % -29.8 % -18.75 %

Back to PMVP Management Effectiveness >> PMVP's 5 Years Annual ROE >> Compare PMVP ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PMVP's' Return on Equity at Yahoo Finance
PMVP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PMVP's Competitors
Subscribers only: Roe for Pmv Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for PMVP's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-08-16T08:48:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.